Insider Trading Pulse — July 23, 2026

CEO Huang Jack Jiajia bought $3.08M of stock at $17.23 under a 10b5-1 plan, the largest insider purchase by value today. This represents a massive vote of confidence from the CEO who now holds 31.5M shares. The 10b5-1 structure suggests pre-planned accumulation, signaling a multi-month bullish thesis

CEO Davis Conn Q. bought $65K at $3.46 and CFO Kearnes Laurilee bought $6.83K at $3.42 on the same day. This coordinated C-suite buying at sub-$3.50 levels is a powerful signal of undervaluation. The CEO's purchase increased his stake by ~550%, showing extreme conviction

EVP & CFO Frey Daniel S. sold $4.06M at $368.16, and EVP & Chief Tech Officer Lefebvre Mojgan M sold $3.39M at $368.35. Combined insider selling of $7.45M from two top executives on the same day at the same price point is a major red flag. Both exercised options first, then immediately sold, suggesting they view the stock as fully valued

Chief Scientific Officer Reich Kristian sold $1M at $20.02 under a 10b5-1 plan. While 10b5-1 plans reduce signaling value, the sale of 50K shares at a $20 level by the CSO is notable given the stock's volatility and the insider's deep knowledge of pipeline progress

Director Imran Mir A bought 36,000 shares at $0.69 for $24.8K. This purchase at sub-$1 levels by a director who already holds 2.1M shares signals confidence in a binary catalyst (likely clinical data) that could re-rate the stock significantly

EVP & Chief Legal Officer Rhodes Kevin H sold $1.31M at $171.20 after exercising options. While option exercises followed by sales are common, the timing at near 52-week highs for 3M suggests the legal chief sees limited near-term upside post the company's restructuring

Director Wrapp Emilie D. bought 3,432 shares at $10.19 for $35K, increasing her stake significantly. Director purchases in closed-end funds often signal a belief the discount to NAV will narrow or that distributions are sustainable

EVP Research & Development Malik Fady Ibraham sold $282K at $80.59 after exercising options at $7.80. The massive gain ($7.80 to $80.59) and sale by the R&D head could signal peak sentiment on the stock's pipeline value, especially given the stock's volatility around FDA decisions

10% owner Olesen Value Fund L.P. sold 372 shares at $29.84 in 4 transactions. While the dollar value is small ($11.1K), the pattern of multiple small sales by a 10% owner at the same price suggests systematic distribution, potentially capping the stock

CEO Baron Christopher F was awarded 52,500 performance units, and EVP Black William J was awarded 75,000 performance units. These large performance-based awards align management with aggressive growth targets, suggesting the bank expects improved profitability and loan growth

Two C-suite executives (CFO and CTO) sold a combined $7.45M on the same day at ~$368. This is the highest-conviction insider selling signal in today's digest. The CFO sold 100% of his exercisable options immediately upon exercise, leaving only 27,534 shares remaining. The CTO sold down to just 7,100 shares, a 99% reduction from her exercised position. This near-total liquidation by top executives is a HIGH RISK signal

Chief Scientific Officer Reich Kristian sold 50,000 shares at $20.02, reducing his stake. For a clinical-stage biotech where scientific leadership is critical, insider selling by the CSO is a significant red flag. The sale represents ~1.8% of his holdings but the signaling value is disproportionate

EVP & Chief Legal Officer sold $1.31M at $171.20. Given 3M's extensive litigation exposure (PFAS, earplugs), the legal chief's decision to sell near highs suggests either personal diversification needs or a view that litigation overhang is not fully resolved

Olesen Value Fund L.P. executed 4 small sales at $29.84, all identical in size. This systematic selling pattern by a major holder could indicate a planned exit strategy. The stock's low liquidity makes this selling more impactful on price

EVP Malik sold $282K at $80.59 after exercising $7.80 options. The 10x gain and sale by the R&D head ahead of potential FDA catalysts (the stock is binary around drug approvals) is concerning. If the R&D chief is taking chips off the table, it may signal lower confidence in pipeline milestones

Six executives (Interim CEO, CFO, President North America, President Global Retail, Chief Legal Officer, Chief Creative Officer) all had shares withheld for taxes on the same day at $21.90. While routine, the volume (24,247 shares withheld, ~$531K total) creates consistent selling pressure. The stock's $21.90 level may act as resistance given this supply

CFO Revol Pierre had 7,461 shares withheld for taxes at $21.68, representing ~31% of his exercised shares. For a REIT, where insider activity is closely watched for signals on NAV, this level of tax withholding is notable

CEO bought $65K at $3.46 and CFO bought $6.83K at $3.42 on the same day. The CEO's purchase increased his stake from ~3,430 to ~22,198 shares (a 547% increase). This coordinated buying at sub-$3.50 levels by both the CEO and CFO is the strongest insider buying signal in the digest. Byrna is a non-lethal defense technology company; insider buying suggests upcoming catalysts (new contracts, product launches) or belief the stock is deeply undervalued

CEO Huang Jack Jiajia bought $3.08M at $17.23 under a 10b5-1 plan. This is the largest insider purchase by value today. The CEO now holds 31.5M shares worth ~$543M at current prices. For a Chinese education company that has pivoted to overseas markets, this level of insider buying suggests the turnaround is gaining traction. The 10b5-1 plan indicates systematic accumulation, not a one-time event

Director Imran Mir A bought 36,000 shares at $0.69 for $24.8K. Rani is a clinical-stage biotech developing oral biologic delivery. The director already held 2.1M shares, so this purchase is a signal of conviction ahead of clinical data readouts. At $0.69, the stock trades at a fraction of its 52-week high, offering asymmetric upside if pipeline data is positive

Seven directors were each awarded 10,000 stock options (right to buy). This is a significant board-level grant that aligns all directors with shareholders. Perma-Fix is a environmental services company focused on nuclear waste treatment. The uniform grant size and timing suggest a strategic initiative or upcoming catalyst that the board is being incentivized to execute on

EVP, CFO & Treasurer Naor Nir was awarded 500,000 shares of common stock. This is a massive grant relative to the company's market cap. Neuronetics is a commercial-stage medical device company (depression treatment). Such a large award suggests aggressive growth targets and potential upcoming milestones (FDA approvals, commercial expansion)

Director Wrapp Emilie D. bought 3,432 shares at $10.19 for $35K. Closed-end fund director purchases are rare and often signal that the fund's discount to NAV is attractive. The purchase increases her stake by ~143%. If the discount narrows, investors could capture both income and capital appreciation

CEO awarded 52,500 and EVP awarded 75,000 performance units. These are tied to performance metrics, suggesting management has high confidence in achieving targets. BayCom is a community bank; performance units typically vest based on ROE, EPS growth, or total shareholder return targets, implying management expects improved profitability

Winmill & Co. Inc bought 4,500 shares at $17.13 and 3,887 shares at $17.20. This 10% owner is systematically adding to its position in this closed-end fund. The purchases at $17.13-17.20 suggest the fund is trading at an attractive discount to NAV, and the 10% owner is signaling confidence in the portfolio's value

Three small-cap companies (Byrna Technologies, Rani Therapeutics, 51Talk) saw significant insider buying today. The CEOs of Byrna and 51Talk made open-market purchases, while a director at Rani added shares. This cluster suggests that insiders at smaller, under-followed companies see value at current levels. The average purchase price across these three was $7.13, with the CEO of 51Talk making the largest commitment at $3.08M. This pattern often precedes operational catalysts or re-ratings

The $7.45M in combined insider selling at Travelers (CFO and CTO) stands in stark contrast to the buying at smaller companies. This is a classic 'smart money' signal where executives at a large, liquid company take profits while insiders at smaller companies deploy capital. The selling at $368 suggests Travelers' management sees limited upside from current levels, potentially due to peak underwriting margins or rising catastrophe losses

Today's digest shows a clear split in biotech insider sentiment. MoonLake Immunotherapeutics (CSO sold $1M) and Cytokinetics (R&D head sold $282K) saw selling, while Rani Therapeutics (director bought $24.8K) saw buying. The sellers are at more advanced stages (MoonLake has Phase 3 data, Cytokinetics has commercial products), while Rani is earlier stage. This suggests insiders at later-stage biotechs are taking profits, while early-stage insiders are adding ahead of catalysts

Perma-Fix Environmental Services awarded 10,000 options to 7 directors in a coordinated grant. This is a board-level alignment strategy that often precedes strategic actions (M&A, spin-offs, major contracts). The uniform grant size suggests a pre-agreed compensation plan, but the timing and concentration are notable. When entire boards receive options simultaneously, it often signals a catalyst-driven period ahead

Three closed-end funds (AllianceBernstein Global High Income, Bexil Investment Trust, BlueBay Destra) saw insider transactions today. Director Wrapp bought AB Global High Income, Winmill & Co bought Bexil, and President Watson redeemed BlueBay shares. This activity suggests the CEF space is seeing divergence - some insiders see value (buying at discounts) while others are redeeming. The buying at AB and Bexil suggests those funds' discounts are attractive

Six MillerKnoll executives had shares withheld for taxes on the same day at $21.90, totaling 24,247 shares (~$531K). This is a routine post-vesting event, but the concentration at a single price point creates a technical overhang. The $21.90 level may act as resistance. This pattern is common across companies with large equity compensation programs and should be monitored for continued selling pressure

Watch for Q2 2026 earnings call (date TBD) after CFO and CTO sold $7.45M in stock. Key questions: Are underwriting margins peaking? Are catastrophe losses accelerating? The insider selling suggests management may guide conservatively. Watch for any commentary on premium growth or loss ratios

CEO and CFO both bought on July 23. Watch for additional insider purchases in the coming weeks. If buying continues, it would confirm the bullish thesis. The stock at $3.46 is near its 52-week low; insider accumulation at these levels is a strong signal. Next catalyst: Q2 earnings (expected August 2026)

CEO Huang's $3.08M purchase was under a 10b5-1 plan. Watch for additional scheduled purchases. The plan structure suggests systematic accumulation. Key catalyst: Q2 2026 earnings showing overseas market traction. The stock at $17.23 has significant upside if the turnaround is working

Seven directors received 10,000 options each. This board-level alignment often precedes a major announcement. Watch for: new nuclear waste contracts, M&A, or government funding awards. The options have a strike price likely near current levels, suggesting management expects the stock to appreciate significantly

CSO Reich sold $1M at $20.02. Watch for additional selling in August 2026 (30-day post-sale period). If the CSO continues to sell, it would be a strong negative signal for the pipeline. Key catalyst: Phase 3 data readout for sonelokimab (hidradenitis suppurativa). The selling ahead of data is concerning

Director Imran bought 36,000 shares at $0.69. Watch for clinical data readouts in H2 2026. The stock at $0.69 is pricing in significant failure risk. If pipeline data is positive, the stock could re-rate significantly. The director's purchase suggests confidence in upcoming milestones

EVP Malik sold $282K at $80.59. Watch for additional insider sales, particularly from the CEO or other C-suite executives. Cytokinetics has a binary FDA decision for aficamten (hypertrophic cardiomyopathy) in 2026. Insider selling ahead of a major catalyst is a red flag. The stock at $80.59 is pricing in approval; any insider selling suggests lower confidence

Six executives had shares withheld at $21.90. Watch for additional vesting events in Q3 2026. The consistent selling pressure at $21.90 may cap the stock. However, if the stock breaks above $22, it would signal that the overhang has been absorbed. Key catalyst: Q2 2026 earnings and any commentary on office furniture demand trends